About: Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
Creator	Barisione, Emanuela De Maria, Andrea Lambertini, Matteo Poggio, Francesca San, Policlinico Tagliamento, Marco Conte, Benedetta Maio, Massimo Mastro, Lucia Ruelle, Tommaso Soldato, Davide Spagnolo, Francesco
Source	Medline; PMC
abstract	BACKGROUND: During COVID‐19 outbreak, oncological care has been reorganized. Cancer patients have been reported to experience a more severe COVID‐19 syndrome; moreover, there are concerns of an interference between immune checkpoint inhibitors (ICIs) and SARS‐CoV‐2 pathogenesis. MATERIALS AND METHODS: Between May 6 and 16, 2020, a 22‐item survey was sent to Italian physicians involved in administering ICIs. It aimed to explore the perception about SARS‐CoV‐2 related risks in cancer patients receiving ICIs, and the attitudes towards their management. RESULTS: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS‐CoV‐2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID‐19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labeled dose of each ICI (55.8%) and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS‐CoV‐2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnea and cough as SARS‐CoV‐2 infected until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune‐related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. CONCLUSIONS: These results highlight the confusion around the perception of a potential interference between ICIs and COVID‐19, supporting the need of focused studies on this topic.
has issue date	2020-06-14(xsd:dateTime)
bibo:doi	10.1111/eci.13315
bibo:pmid	32535890
has license	no-cc
sha1sum (hex)	14f91b67f34e3ac4aaa752a2bb34caa5c5f0ef68
schema:url	https://doi.org/10.1111/eci.13315
resource representing a document's title	Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
has PubMed Central identifier	PMC7323025
has PubMed identifier	32535890
schema:publication	Eur J Clin Invest
resource representing a document's body	covid:14f91b67f34e3ac4aaa752a2bb34caa5c5f0ef68#body_text
is schema:about of	named entity 'COVID-19' covid:arg/14f91b67f34e3ac4aaa752a2bb34caa5c5f0ef68 named entity 'SARS-CoV-2' named entity 'COVID-19 outbreak' named entity 'immunotherapy' named entity 'European Society for Medical Oncology' named entity 'hyperinflammation' named entity 'ICIs' named entity 'antitumor' named entity 'SARS-CoV-2' named entity 'stage III melanoma' named entity 'comorbidities' named entity 'CRS' named entity 'pathogenesis' named entity 'pathogenesis' named entity 'viral infection' named entity 'pathogenesis' named entity 'pathogenesis' named entity 'infection' named entity 'checkpoint blockade' named entity 'COVID-19 outbreak' named entity 'COVID-19 outbreak' named entity 'ICIs' named entity 'risk factors' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'lung' named entity 'oncology' named entity 'ICIs' named entity 'impact of COVID-19' named entity 'kidney cancer' named entity 'COVID' named entity 'platinum-based doublet' named entity 'ICIs' named entity 'kidney cancer' named entity 'ICIs' named entity 'higher risk' named entity 'ICIs' named entity 'SARS-CoV-2' named entity 'infection' named entity 'ICI' named entity 'cancer care' named entity 'inflammatory response' named entity 'pathogenesis' named entity 'descriptive statistics' named entity 'CRS' named entity 'differential diagnosis' named entity 'NSCLC' named entity 'SARS-CoV-2' named entity 'ICIs' named entity 'SARS-CoV-2' named entity 'ICIs' named entity 'clinical practice' named entity 'SARS-CoV-2' named entity 'ICIs' named entity 'COVID' named entity 'melanoma' named entity 'COVID-19' named entity 'bladder cancer' named entity 'nab-paclitaxel' named entity 'mechanism of action' named entity 'lung cancer' named entity 'pneumonia' named entity 'renal cell carcinoma' named entity 'corticosteroids' named entity 'SARS-CoV-2' named entity 'second-line therapy' named entity 'SARS-CoV-2' named entity 'differential diagnosis' named entity 'oncology'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software